Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 61.33 CNY -5.5% Market Closed
Market Cap: 45.5B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

Hangzhou Tigermed Consulting Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hangzhou Tigermed Consulting Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Net Issuance of Debt
ÂĄ529.9m
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
13%
WuXi AppTec Co Ltd
SSE:603259
Net Issuance of Debt
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Net Issuance of Debt
-ÂĄ301.7m
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Net Issuance of Debt
-ÂĄ765.3m
CAGR 3-Years
N/A
CAGR 5-Years
-144%
CAGR 10-Years
N/A
M
MGI Tech Co Ltd
SSE:688114
Net Issuance of Debt
ÂĄ249.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Net Issuance of Debt
-ÂĄ75.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hangzhou Tigermed Consulting Co Ltd
Glance View

Market Cap
45.5B CNY
Industry
Life Sciences Tools & Services

Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical trial and consulting organization based in China, dedicated to facilitating the development of innovative medical therapies. Founded in 2002, the company has rapidly ascended to prominence by leveraging its deep expertise in clinical research while providing comprehensive services that encompass all phases of clinical trials. With a robust portfolio that includes over 4,000 completed projects, Tigermed stands out for its strong focus on quality, efficiency, and regulatory compliance. Serving a diverse clientele of pharmaceutical and biotechnology companies, the firm positions itself as a vital partner in navigating the complexities of the drug development process, particularly in fast-growing Asian markets. An investor looking at Tigermed will find a company that is not only well-established but also poised for significant growth amidst rising global healthcare demands. With a strategic emphasis on expanding its geographic footprint and enhancing technological capabilities, Tigermed is capitalizing on the increasing investment in life sciences, particularly in China and surrounding regions. By harnessing big data analytics and innovative methodologies, the company is well-equipped to streamline clinical operations, reduce costs, and accelerate time-to-market for life-saving treatments. As the global healthcare landscape continues to evolve, Tigermed’s commitment to fostering advancements in clinical research places it in an advantageous position, making it an attractive prospect for investors seeking exposure in the burgeoning healthcare sector.

Intrinsic Value
70.64 CNY
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Hangzhou Tigermed Consulting Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
529.9m CNY

Based on the financial report for Sep 30, 2024, Hangzhou Tigermed Consulting Co Ltd's Net Issuance of Debt amounts to 529.9m CNY.

What is Hangzhou Tigermed Consulting Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
13%

Over the last year, the Net Issuance of Debt growth was -42%. The average annual Net Issuance of Debt growth rates for Hangzhou Tigermed Consulting Co Ltd have been 20% over the past three years , 20% over the past five years , and 13% over the past ten years .

Back to Top